{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:06:42Z","timestamp":1790719602433,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jagp.2025.08.002","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:31:44Z","timestamp":1771590704000},"page":"602-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clozapine in Older Adults: Benefits and Challenges"],"prefix":"10.1016","volume":"34","author":[{"given":"Rachel","family":"Moster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Awatramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S.","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jagp.2025.08.002_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin","year":"2020","journal-title":"NPJ Schizophrenia"},{"issue":"2","key":"10.1016\/j.jagp.2025.08.002_bib0002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophr Bull"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.002_bib0003","doi-asserted-by":"crossref","first-page":"e6051","DOI":"10.1002\/gps.6051","article-title":"Side effects of clozapine in older adults with treatment-resistant schizophrenia compared to younger adults","volume":"39","author":"Groenewald","year":"2024","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.jagp.2025.08.002_bib0004","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/schbul\/sbad030","article-title":"Clozapine optimization: a Delphi consensus guideline from the treatment response and resistance in psychosis working group","volume":"49","author":"Wagner","year":"2023","journal-title":"Schizophr Bull"},{"issue":"7","key":"10.1016\/j.jagp.2025.08.002_bib0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.002_bib0006","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jagp.2025.08.002_bib0007","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl 2","key":"10.1016\/j.jagp.2025.08.002_bib0008","first-page":"5","article-title":"Expert consensus panel for using antipsychotic drugs in older P. Using antipsychotic agents in older patients","volume":"65","author":"Alexopoulos","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.jagp.2025.08.002_bib0009","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00228-024-03690-w","article-title":"Effect of propranolol on pharmacokinetics of clozapine in schizophrenic patients: a meta-analysis","volume":"80","author":"Yang","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jagp.2025.08.002_bib0010","first-page":"1097","article-title":"Be an inhibitor of clozapine metabolism, as seen in 5 patients: 2 from a US double-blind study and 3 from a German TDM study","volume":"10","author":"Schoretsanitis","year":"2022","journal-title":"Therapeut Drug Monitor"},{"key":"10.1016\/j.jagp.2025.08.002_bib0011","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajp.2018.03.008","article-title":"Clozapine use in geriatric patients- Challenges","volume":"33","author":"Mukku","year":"2018","journal-title":"Asian J Psychiatr"},{"issue":"1-3","key":"10.1016\/j.jagp.2025.08.002_bib0012","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2009.01.002","article-title":"The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis","volume":"109","author":"Tiihonen","year":"2009","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.002_bib0013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40266-013-0144-2","article-title":"Adverse effects of clozapine in older patients: epidemiology, prevention and management","volume":"31","author":"Bishara","year":"2014","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.002_bib0014","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bcp.15691","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","volume":"90","author":"Reeves","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jagp.2025.08.002_bib0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/acps.13398","article-title":"Risk factors for clozapine-induced myocarditis and cardiomyopathy: a systematic review and meta-analysis","volume":"145","author":"Vickers","year":"2022","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"10.1016\/j.jagp.2025.08.002_bib0016","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","article-title":"Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases","volume":"69","author":"Palmer","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"10.1016\/j.jagp.2025.08.002_bib0017","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1176\/appi.ajp.20230744","article-title":"High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: a finish 25-year follow-up register study","volume":"181","author":"Partanen","year":"2024","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.jagp.2025.08.002_bib0018","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1192\/bjp.2024.140","article-title":"Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada","volume":"225","author":"Balbuena","year":"2024","journal-title":"Br J Psychiatry"},{"issue":"8","key":"10.1016\/j.jagp.2025.08.002_bib0019","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/17425255.2024.2373111","article-title":"Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia","volume":"20","author":"de Leon","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"10.1016\/j.jagp.2025.08.002_bib0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland","volume":"11","author":"Rubio","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.jagp.2025.08.002_bib0021","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-2003-41201","article-title":"Delirium during clozapine treatment: incidence and associated risk factors","volume":"36","author":"Centorrino","year":"2003","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.jagp.2025.08.002_bib0022","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1212\/WNL.41.3.369","article-title":"Clozapine-related seizures","volume":"41","author":"Devinsky","year":"1991","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jagp.2025.08.002_bib0023","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/0091217420972827","article-title":"Delirium on clozapine: a tale of friend turned foe-a case report","volume":"56","author":"Das","year":"2021","journal-title":"Int J Psychiatry Med"},{"issue":"5","key":"10.1016\/j.jagp.2025.08.002_bib0024","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0924-977X(03)00042-7","article-title":"Toxic rise of clozapine plasma concentrations in relation to inflammation","volume":"13","author":"Haack","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.jagp.2025.08.002_bib0025","article-title":"Consensus statement on the use of clozapine during the COVID-19 pandemic","volume":"45","author":"Siskind","year":"2020","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"10.1016\/j.jagp.2025.08.002_bib0026","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JCP.0000000000001987","article-title":"Letter to the FDA proposing major changes in the US clozapine package insert supported by clozapine experts worldwide. Part I: a review of the pharmacokinetic literature and proposed changes","volume":"45","author":"de Leon","year":"2025","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.jagp.2025.08.002_bib0027","doi-asserted-by":"crossref","DOI":"10.7326\/AITC202310170","article-title":"Covid-19","volume":"176","author":"Marks","year":"2023","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jagp.2025.08.002_bib0028","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/JCP.0000000000001828","article-title":"Question: how should i monitor and adjust the clozapine dose for my patients who develop COVID and could benefit from nirmatrelvir\/ritonavir?","volume":"44","author":"de Leon","year":"2024","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jagp.2025.08.002_bib0029","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1532-5415.2007.01625.x","article-title":"Antipsychotic drug use and risk of pneumonia in elderly people","volume":"56","author":"Knol","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.002_bib0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/wps.20707","article-title":"Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics","volume":"19","author":"de Leon","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jagp.2025.08.002_bib0031","first-page":"165","article-title":"Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)","volume":"268","author":"De Las Cuevas","year":"2024","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.002_bib0032","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/schbul\/sbac139","article-title":"Women with schizophrenia-spectrum disorders after menopause: a vulnerable group for relapse","volume":"49","author":"Sommer","year":"2023","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jagp.2025.08.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1177\/2045125319859973","article-title":"The association between hormones and antipsychotic use: a focus on postpartum and menopausal women","volume":"9","author":"Gonzalez-Rodriguez","year":"2019","journal-title":"Ther Adv Psychopharmacol"},{"issue":"8","key":"10.1016\/j.jagp.2025.08.002_bib0034","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14656566.2018.1465563","article-title":"Pharmacotherapy for schizophrenia in postmenopausal women","volume":"19","author":"Gonzalez-Rodriguez","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"10.1016\/j.jagp.2025.08.002_bib0035","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.jagp.2025.08.002_bib0036","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"The anticholinergic risk scale and anticholinergic adverse effects in older persons","volume":"168","author":"Rudolph","year":"2008","journal-title":"Arch Int Med"},{"issue":"16","key":"10.1016\/j.jagp.2025.08.002_bib0037","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2023.26942","article-title":"Falls prevention for older adults","volume":"331","author":"Leung","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jagp.2025.08.002_bib0038","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/JCP.0000000000001605","article-title":"Clozapine blood concentration predicts corrected QT-interval prolongation in patients with psychoses","volume":"42","author":"Kim","year":"2022","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jagp.2025.08.002_bib0039","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/17425255.2014.885504","article-title":"Clinically relevant interactions between newer antidepressants and second-generation antipsychotics","volume":"10","author":"Spina","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.jagp.2025.08.002_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11096-016-0414-2","article-title":"Risk factors for QTc-prolongation: systematic review of the evidence","volume":"39","author":"Vandael","year":"2017","journal-title":"Int J Clin Pharma"},{"issue":"8","key":"10.1016\/j.jagp.2025.08.002_bib0041","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.4088\/JCP.08m04495","article-title":"Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study","volume":"70","author":"Sockalingam","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.jagp.2025.08.002_bib0042","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40262-020-00944-5","article-title":"Elevated clozapine concentrations in clozapine-treated patients with hypersalivation","volume":"60","author":"Schoretsanitis","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.jagp.2025.08.002_bib0043","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/17425255.2024.2343020","article-title":"Optimizing co-prescription of clozapine and antiseizure medications: a systematic review and expert recommendations for clinical practice","volume":"20","author":"Verdoux","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.jagp.2025.08.002_bib0044","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0006-3223(95)00499-8","article-title":"Clozapine-induced myoclonus and generalized seizures","volume":"39","author":"Sajatovic","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jagp.2025.08.002_bib0045","unstructured":"New York State Office of Mental Health (OMH). (2022). Clinical Advisory on Paxlovid Treatment for COVID-19 Positive and Symptomatic Patients Currently on Clozapine. https:\/\/omh.ny.gov\/omhweb\/advisories\/clinical-advisory-treatment-with-paxlovid-1-12-2022.pdf. Accessed September 3, 2025."}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748125004348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748125004348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:42:10Z","timestamp":1772109730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748125004348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1064748125004348"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2025.08.002","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine in Older Adults: Benefits and Challenges","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}